PortalPublikationenHLH-2004: Diagnostic and therapeutic guidelines for hemophag...

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

Standard

HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. / Henter, Jan-Inge; Horne, Annacarin; Aricó, Maurizio; Egeler, R Maarten; Filipovich, Alexandra H; Imashuku, Shinsaku; Ladisch, Stephan; McClain, Ken; Webb, David; Winiarski, Jacek; Janka-Schaub, Gritta.

in: PEDIATR BLOOD CANCER, Jahrgang 48, Nr. 2, 2, 2007, S. 124-131.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Henter, J-I, Horne, A, Aricó, M, Egeler, RM, Filipovich, AH, Imashuku, S, Ladisch, S, McClain, K, Webb, D, Winiarski, J & Janka-Schaub, G 2007, 'HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.', PEDIATR BLOOD CANCER, Jg. 48, Nr. 2, 2, S. 124-131. <http://www.ncbi.nlm.nih.gov/pubmed/16937360?dopt=Citation>

APA

Henter, J-I., Horne, A., Aricó, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., McClain, K., Webb, D., Winiarski, J., & Janka-Schaub, G. (2007). HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. PEDIATR BLOOD CANCER, 48(2), 124-131. [2]. http://www.ncbi.nlm.nih.gov/pubmed/16937360?dopt=Citation

Vancouver

Henter J-I, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. PEDIATR BLOOD CANCER. 2007;48(2):124-131. 2.

Bibtex

@article{c7e6efdd68ee45f29a5dfb70fabb65a7,
title = "HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.",
abstract = "In HLH-94, the first prospective international treatment study for hemophagocytic lymphohistiocytosis (HLH), diagnosis was based on five criteria (fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or hypofibrinogenemia, and hemophagocytosis). In HLH-2004 three additional criteria are introduced; low/absent NK-cell-activity, hyperferritinemia, and high-soluble interleukin-2-receptor levels. Altogether five of these eight criteria must be fulfilled, unless family history or molecular diagnosis is consistent with HLH. HLH-2004 chemo-immunotherapy includes etoposide, dexamethasone, cyclosporine A upfront and, in selected patients, intrathecal therapy with methotrexate and corticosteroids. Subsequent hematopoietic stem cell transplantation (HSCT) is recommended for patients with familial disease or molecular diagnosis, and patients with severe and persistent, or reactivated, disease. In order to hopefully further improve diagnosis, therapy and biological understanding, participation in HLH studies is encouraged.",
author = "Jan-Inge Henter and Annacarin Horne and Maurizio Aric{\'o} and Egeler, {R Maarten} and Filipovich, {Alexandra H} and Shinsaku Imashuku and Stephan Ladisch and Ken McClain and David Webb and Jacek Winiarski and Gritta Janka-Schaub",
year = "2007",
language = "Deutsch",
volume = "48",
pages = "124--131",
journal = "PEDIATR BLOOD CANCER",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.

AU - Henter, Jan-Inge

AU - Horne, Annacarin

AU - Aricó, Maurizio

AU - Egeler, R Maarten

AU - Filipovich, Alexandra H

AU - Imashuku, Shinsaku

AU - Ladisch, Stephan

AU - McClain, Ken

AU - Webb, David

AU - Winiarski, Jacek

AU - Janka-Schaub, Gritta

PY - 2007

Y1 - 2007

N2 - In HLH-94, the first prospective international treatment study for hemophagocytic lymphohistiocytosis (HLH), diagnosis was based on five criteria (fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or hypofibrinogenemia, and hemophagocytosis). In HLH-2004 three additional criteria are introduced; low/absent NK-cell-activity, hyperferritinemia, and high-soluble interleukin-2-receptor levels. Altogether five of these eight criteria must be fulfilled, unless family history or molecular diagnosis is consistent with HLH. HLH-2004 chemo-immunotherapy includes etoposide, dexamethasone, cyclosporine A upfront and, in selected patients, intrathecal therapy with methotrexate and corticosteroids. Subsequent hematopoietic stem cell transplantation (HSCT) is recommended for patients with familial disease or molecular diagnosis, and patients with severe and persistent, or reactivated, disease. In order to hopefully further improve diagnosis, therapy and biological understanding, participation in HLH studies is encouraged.

AB - In HLH-94, the first prospective international treatment study for hemophagocytic lymphohistiocytosis (HLH), diagnosis was based on five criteria (fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or hypofibrinogenemia, and hemophagocytosis). In HLH-2004 three additional criteria are introduced; low/absent NK-cell-activity, hyperferritinemia, and high-soluble interleukin-2-receptor levels. Altogether five of these eight criteria must be fulfilled, unless family history or molecular diagnosis is consistent with HLH. HLH-2004 chemo-immunotherapy includes etoposide, dexamethasone, cyclosporine A upfront and, in selected patients, intrathecal therapy with methotrexate and corticosteroids. Subsequent hematopoietic stem cell transplantation (HSCT) is recommended for patients with familial disease or molecular diagnosis, and patients with severe and persistent, or reactivated, disease. In order to hopefully further improve diagnosis, therapy and biological understanding, participation in HLH studies is encouraged.

M3 - SCORING: Zeitschriftenaufsatz

VL - 48

SP - 124

EP - 131

JO - PEDIATR BLOOD CANCER

JF - PEDIATR BLOOD CANCER

SN - 1545-5009

IS - 2

M1 - 2

ER -